NYSEAM:MTNB - Post Discussion
Post by
whytestocks on Feb 26, 2024 2:45pm
Matinas BioPharma Provides Positive Outcomes Update on the M
BREAKING NEWS: $MTNB Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionA total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and endemic mycoses such as coccidioidomycosis and histoplasmosis All 5 patients who completed the desired co...
MTNB - Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
Be the first to comment on this post